Navigation Links
Argos Therapeutics to Present Overview of its Arcelis™ Dendritic Cell-based Immunotherapy, Participate in Panel Discussion at Inaugural Cancer Immunotherapy Conference
Date:10/18/2010

DURHAM, N.C., Oct. 18 /PRNewswire/ -- Argos Therapeutics today announced that Jeff Abbey, the company's president and chief executive officer, will present an overview of its Arcelis™ dendritic cell-based immunotherapy at 3:30 p.m. EDT on Oct. 21 at the inaugural Cancer Immunotherapy Conference in New York.

In addition, Charles Nicolette, Ph.D., the company's chief scientific officer and vice president of research and development, will participate in a panel discussion titled "Autologous versus allogeneic immunotherapy" at 2:45 p.m. EDT that day. The conference will take place at the New York Academy of Medicine. A live Webcast of the conference can be accessed by visiting www.mdbpartners.com/vaccine.

About the Arcelis™ Technology

Arcelis is Argos' proprietary technology for personalizing RNA-loaded dendritic cell immunotherapies for cancer, HIV and other infectious diseases. This platform is based on optimizing a patient's own (autologous) dendritic cells to trigger a tumor- or pathogen-specific immune response. To address the challenge of the unique genetic profile of each patient's disease and the genetic mutations of that disease, Argos loads the autologous dendritic cells with a sample of messenger RNA ("mRNA") isolated from the patient's disease. Through this process, dendritic cells can potentially prime immune responses to the entire antigenic repertoire, resulting in an immunotherapeutic that is customized to the patient's specific disease.

About Argos Therapeutics, Inc.Argos is an immunotherapy company developing new treatments for cancer, infectious and autoimmune diseases and transplantation rejection. The Company has generated multiple platform technologies and a diverse pipeline of products based on its expertise in the biology of dendritic cells — the master switch that turns the immune system on or off. www.argostherapeutics.com Contacts:David Schull or Andreas MarathovouniotisRusso Partners LLC(212) 845-4271 or (212) 845-4235david.schull@russopartnersllc.com or andreas.marathis@russopartnersllc.comJeff AbbeyArgos Therapeutics(919) 287-6308jabbey@argostherapeutics.com
'/>"/>

SOURCE Argos Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Argos Therapeutics to Present Recent Clinical Developments and Corporate Overview at 18th Annual BioPartnering Europe
2. Results From Argos Therapeutics Arcelis™ Immunotherapy Phase 2 Study for Treatment of Renal Cell Carcinoma (RCC) Accepted for Poster Presentation at Ninth International Kidney Cancer Symposium
3. Talecris Biotherapeutics Receives FDA Approval for Gamunex®-C
4. Prime Therapeutics Announces URAC Accreditation
5. Halozyme Therapeutics Announces Implementation of Development Focused Strategy
6. Talecris Biotherapeutics to Report Third Quarter 2010 Financial Results
7. Michael R. Bristow, M.D. Ph.D. Joins Nile Therapeutics Scientific Advisory Board
8. Halozyme Therapeutics to Host Analyst Meeting on October 14 in New York
9. Prime Therapeutics Hires Peter Wickersham, Senior Vice President Cost of Care
10. Osseon® Therapeutics Introduces New Osseoflex® DR Steerable Bone Drill
11. Weikang Bio-Technology Plans to Launch New Therapeutics in First Quarter 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/11/2017)... 11, 2017 DarioHealth Corp. (NASDAQ: DRIO), a ... big data solutions, today announced that it will release ... and host a conference call at 9:00am ET. The ... financial results and its strategy and outlook for the ... Erez Raphael , Chief Executive Officer, and ...
(Date:8/7/2017)... 2017 Insightin Health, provider of data-driven ... engagement, announced the selection of Michael Wood ... effective as of February 2017. In this role, Wood ... for our clients. Wood brings with him more ... business analytics within the healthcare industry. Wood formerly ...
(Date:8/7/2017)... -- Endo International plc (NASDAQ: ENDP ) today ... known U.S. mesh product liability claims and that it ... U.S. claims at reasonable values. Under the agreements, Endo ... of 2017 and continuing through the fourth quarter of ... the Company intends to increase its mesh product liability ...
Breaking Medicine Technology:
(Date:8/21/2017)... ... August 21, 2017 , ... Marathon ... all over the country. , Outdoor running increases exposure to ultraviolet radiation, a ... increased risk of melanoma, and only half may be adequately protecting themselves with ...
(Date:8/21/2017)... (PRWEB) , ... August 21, 2017 , ... San Diego ... ) health care reform plan, has announced his candidacy for the 52nd Congressional District ... and shared in America’s Promise. Coming to this country at age eleven after suffering ...
(Date:8/20/2017)... ... ... State Farm Neighborhood Assist® has named The Southern Maryland Team Anti-Bullying Program ... initiative wins, Gals Lead – Dream Queen Foundation’s signature teen girl program to help ... Calvert and Charles Counties. The program could potentially impact nearly 17,500 female students (49.4 ...
(Date:8/19/2017)... MD (PRWEB) , ... August 18, 2017 , ... ... and Drug Administration Reauthorization Act of 2017, legislation that provides for greater public ... mild to moderate hearing loss to access OTC hearing aids without being seen ...
(Date:8/19/2017)... ... August 19, 2017 , ... Parker at Stonegate, an assisted ... passionate employees, caregivers, volunteers, thought leaders, researchers, educators and partners leading the way ... time to refresh the carpeting with the goal of maintaining the same precise ...
Breaking Medicine News(10 mins):